Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-816336 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| BMS-816336 or placebo (Panel 1) | ACTIVE_COMPARATOR | - |
| BMS-816336 or placebo (Panel 2) | ACTIVE_COMPARATOR | - |
| BMS-816336 or placebo (Panel 3) | ACTIVE_COMPARATOR | - |
| BMS-816336 or placebo (Panel 4) | ACTIVE_COMPARATOR | - |
| BMS-816336 or placebo (Panel 5) | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BMS-816336 | DRUG | Suspension, Oral, 15 mg Active, Once on Day 1 only, 4 days |
| Placebo | DRUG | Suspension, Oral, 0 mg, Once on Day 1 only, 4 days |
Inclusion Criteria: * Healthy male subjects * BMI of 18 to 32 kg/m² * Men only, ages 18-55 years Exclusion Criteria: * Sexually active men not using effective birth control if their partners are WOCBP * Any significant acute or chronic medical illness * Family history of Gilbert's disease * Histo...
BMS-816336 is an investigational small molecule being studied for the treatment of non-insulin-dependent diabetes mellitus, also known as type 2 diabetes. It is being developed by Bristol-Myers Squibb Company. The drug is in Phase 1 clinical development and is not yet approved by the FDA.
BMS-816336 is being developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for the treatment of non-insulin-dependent diabetes mellitus.
BMS-816336 is currently in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. One Phase 1 trial has been completed, which studied the safety of BMS-816336 in healthy male subjects.
BMS-816336 has one completed clinical trial registered under NCT00979368, titled "Safety Study of BMS-816336 in Healthy Male Subjects." This Phase 1 trial enrolled 40 participants in Australia and was a randomized, double-blind, active-controlled study.
The molecular target of BMS-816336 has not been disclosed in available information. As a small molecule, it is designed to interact with biological pathways involved in glucose metabolism, but the specific mechanism of action has not been publicly detailed.